Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 893

1.

Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.

Di Prospero LS, Seminsky M, Honeyford J, Doan B, Franssen E, Meschino W, Chart P, Warner E.

CMAJ. 2001 Apr 3;164(7):1005-9.

2.

Factors associated with decisions about clinical BRCA1/2 testing.

Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B.

Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1251-4.

3.
4.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

5.

Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing.

Lodder L, Frets PG, Trijsburg RW, Klijn JG, Seynaeve C, Tilanus MM, Bartels CC, Meijers-Heijboer EJ, Verhoog LC, Niermeijer MF.

Am J Med Genet A. 2003 Jun 15;119A(3):266-72.

PMID:
12784290
6.

Psychological impact of receiving a BRCA1/BRCA2 test result.

Lodder L, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Duivenvoorden HJ, Tibben A, Wagner A, van der Meer CA, van den Ouweland AM, Niermeijer MF.

Am J Med Genet. 2001 Jan 1;98(1):15-24.

PMID:
11426450
7.

Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.

Vasen HF, Haites NE, Evans DG, Steel CM, Møller P, Hodgson S, Eccles D, Morrison P, Stoppa Lyonet D, Chang-Claude J, Caligo M.

Eur J Cancer. 1998 Nov;34(12):1922-6.

PMID:
10023316
8.

BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.

McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP.

Am J Med Genet A. 2005 Mar 1;133A(2):165-9.

PMID:
15633195
9.

Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2.

Phillips KA, Warner E, Meschino WS, Hunter J, Abdolell M, Glendon G, Andrulis IL, Goodwin PJ.

Clin Genet. 2000 May;57(5):376-83.

PMID:
10852372
10.
11.

Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.

J Clin Oncol. 2003 May 1;21(9):1675-81.

PMID:
12721241
12.

Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.

Lodder L, Frets PG, Trijsburg RW, Tibben A, Meijers-Heijboer EJ, Duivenvoorden HJ, Wagner A, van Der Meer CA, Devilee P, Cornelisse CJ, Niermeijer MF.

Eur J Hum Genet. 2001 Jul;9(7):492-500.

13.

BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.

McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP.

Am J Med Genet A. 2004 Oct 15;130A(3):221-7.

PMID:
15378542
14.

Psychological issues among children of hereditary breast cancer gene (BRCA1/2) testing participants.

Tercyak KP, Peshkin BN, Streisand R, Lerman C.

Psychooncology. 2001 Jul-Aug;10(4):336-46.

PMID:
11462232
15.

Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.

Schwartz MD, Lerman C, Brogan B, Peshkin BN, Isaacs C, DeMarco T, Halbert CH, Pennanen M, Finch C.

Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1003-7.

16.

Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.

Kuschel B, Lux MP, Goecke TO, Beckmann MW.

Eur J Cancer Prev. 2000 Jun;9(3):139-50. Review.

PMID:
10954253
17.

Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families.

Biesecker BB, Ishibe N, Hadley DW, Giambarresi TR, Kase RG, Lerman C, Struewing JP.

Am J Med Genet. 2000 Aug 14;93(4):257-63.

PMID:
10946349
18.

Overestimation of hereditary breast cancer risk.

Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ.

Ann Surg. 1998 Sep;228(3):375-84.

19.

Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.

Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T, Lawrence W, Main D, Finch C, Magnant C, Pennanen M, Tsangaris T, Willey S, Isaacs C.

J Clin Oncol. 2004 May 15;22(10):1823-9. Epub 2004 Apr 5.

PMID:
15067026
20.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901

Supplemental Content

Support Center